Bristol-Myers Squibb researchers to present data on Opdivo, Yervoy.
+ Technology/Innovation
Jamie Barrand | Mar 20, 2016

Bristol-Myers Squibb researchers to present data on Opdivo, Yervoy

New clinical research data about Bristol-Myers Squibb Co.’s immuno-oncology therapies Opdivo and Yervoy are set to be unveiled April 16-20 at the American Association for Cancer Research’s (AACR) Annual Meeting in New Orleans, Lousiana.

Researchers from Bristol-Myers Squibb’s oncology division have been testing and developing both products on different tumor types and difficult-to-treat cancers -- and have proven Opdivo and Yervoy can extend survival for some cancer patients.

“At this year’s AACR, we are excited to present, for the first time, overall survival data from the first pivotal phase-three trial of an immuno-oncology agent, Opdivo -- in previously treated squamous cell carcinoma of the head and neck, a cancer that has had very few treatment advances over the past 10 years,” Jean Viallet, global clinical research lead for Bristol-Myers Squibb’s oncology division, said. “These head and neck cancer data represent the fifth tumor type with overall survival data for Opdivo compared to a standard of care. We will also be presenting overall survival data from CheckMate -069, which was the first randomized trial to evaluate the Opdivo + Yervoy Regimen in the first-line setting for advanced melanoma, and has been a foundational study in building our scientific understanding of combining these two immuno-oncology agents to treat this form of cancer.”

Organizations in this story

More News